FRONT PAGE AMPYRA AUBAGIO AVONEX BETASERON COPAXONE EXTAVIA
Stan's Angels MS News Channel on YouTube GILENYA NOVANTRONE REBIF RITUXAN TECFIDERA TYSABRI
 Daily News for Neuros, Nurses & Savvy MSers: 208,152 Viewers, 8,368 Stories & Studies
Click Here For My Videos, Advice, Tips, Studies and Trials.
Timothy L. Vollmer, MD
Department of Neurology
University of Colorado Health Sciences Center Professor

Co-Director of the RMMSC at Anschutz Medical Center

Medical Director-Rocky Mountain MS Center
Click here to read my columns
Brian R. Apatoff, MD, PhD
Multiple Sclerosis Institute
Center for Neurological Disorders

Associate Professor Neurology and Neuroscience,

Weill Medical College of Cornell University

Clinical Attending in Neurology,
New York-Presbyterian Hospital
CLICK ON THE RED BUTTON BELOW
You'll get FREE Breaking News Alerts on new MS treatments as they are approved
MS NEWS ARCHIVES: by week

HERE'S A FEW OF OUR 6000+ Facebook & MySpace FRIENDS
Timothy L. Vollmer M.D.
Department of Neurology
University of Colorado Health Sciences Center
Co-Director of the RMMSC at Anschutz Medical Center
and
Medical Director-Rocky Mountain MS Center


Click to view 1280 MS Walk photos!

"MS Can Not
Rob You of Joy"
"I'm an M.D....my Mom has MS and we have a message for everyone."
- Jennifer Hartmark-Hill MD
Beverly Dean

"I've had MS for 2 years...this is the most important advice you'll ever hear."
"This is how I give myself a painless injection."
Heather Johnson

"A helpful tip for newly diagnosed MS patients."
"Important advice on choosing MS medication "
Joyce Moore


This page is powered by Blogger. Isn't yours?

Saturday

 

Elan dealt a blow as rival drug, Gilenya, approved

(Posted By: Josi Creek)

ELAN, the Athlone-based pharmaceuticals company, has been dealt a blow after a rival to one of its leading drugs was approved by US regulators. The share dealt 2.5pc lower in New York yesterday.






Gilenya, a drug used to treat multiple sclerosis, was approved unanimously yesterday by the Food and Drug Administration drugs advisory committee as part of the process that will see the drug eventually reach the market in the US and worldwide.
While the approval was expected, the committee unexpectedly approved the drug as a potential first-line therapy, adding to the competition for Elan's Tysabri. Gilenya is made by Swiss company Novartis.
Bloxham stockbrokers were pessimistic about Tysabri's future. "With Tysabri revenues already slowing in recent months, this announcement will do little to boost investor sentiment in the stock and will lead to further cuts in projected future Tysabri revenues."
Ian Hunter at Goodbody said up to 10pc of patients now on Tysabri may switch to Gilenya. "But we believe that Tysabri's undoubtedly superior efficacy will continue to attract patients when they experience disease breakthrough over time on other MS drugs, including Gilenya," he said.

Labels: ,



Go to Newer News Go to Older News